<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358981</url>
  </required_header>
  <id_info>
    <org_study_id>13747</org_study_id>
    <secondary_id>I4P-FW-GPFA</secondary_id>
    <nct_id>NCT01358981</nct_id>
  </id_info>
  <brief_title>A Study of LY2881835 in Healthy People and People With Diabetes</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Oral Doses of LY2881835 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be the first study in which LY2881835 is given to humans in order to evaluate the
      safety and any side effects of LY2881835 in humans as well as how long LY2881835 stays in the
      body and its effect on blood sugar levels.

      The study consists of two parts. In part A, healthy subjects will participate and in part B,
      patients with type 2 Diabetes Mellitus (T2DM) will participate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2011</start_date>
  <completion_date type="Actual">August 17, 2011</completion_date>
  <primary_completion_date type="Actual">August 17, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Adverse Effects</measure>
    <time_frame>Baseline to study completion up to 3 months</time_frame>
    <description>Clinically significant adverse effects are treatment emergent adverse events (TEAEs) possibly related to study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Curve (AUC) of LY2881835</measure>
    <time_frame>Part A: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24hours (h) post-dose; Part B: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose</time_frame>
    <description>Not all the participants had quantifiable plasma concentrations at 48 hours, therefore only AUC from time zero to 24 hours [AUC(0-24 hours)] is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) Of LY2881835</measure>
    <time_frame>Part A: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose; Part B: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose</time_frame>
    <description>Not all the participants had quantifiable plasma concentrations at 48 hours, therefore only Cmax up to 24 hours post-dose is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of LY2881835</measure>
    <time_frame>Part A: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose; Part B: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose</time_frame>
    <description>Not all the participants had quantifiable plasma concentrations at 48 hours, therefore only Tmax up to 24 hours post dose is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Area Under the Effective Concentration Curve (AUEC)</measure>
    <time_frame>Part A: Predose, 1.0, 1.5, 2.5, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18 and 24 h post-dose; Part B: Predose, 1.0, 1.5, 2.5, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18 and 24 h post-dose</time_frame>
    <description>Glucose area under the serum concentration versus time curve (AUEC) was calculated using the linear trapezoidal rule from time 0 to 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-Like Peptide (Active GLP-1) Area Under the Effective Concentration Curve (AUEC)</measure>
    <time_frame>Part A: Predose, 1.5 and 2.5 h post-dose; Part B: Predose, 1.5 and 2.5 h post-dose</time_frame>
    <description>Glucagon-like peptide (active GLP-1) area under the serum concentration versus time curve (AUEC) was calculated using the linear trapezoidal rule from time 0 to 2.5 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Peptide Area Under the Effective Concentration Curve (AUEC)</measure>
    <time_frame>Part A: Predose, 1.0, 1.5, 2.5, 4, 5, 6 and 24 h post-dose; Part B: Predose, 1.0, 1.5, 2.5, 4, 5, 6 and 24 h post-dose</time_frame>
    <description>C-Peptide area under the serum concentration versus time curve (AUEC) was calculated using the linear trapezoidal rule from time 0 to 6 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY2881835</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cohort of healthy participants will receive single oral doses of LY2881835 in up to 3 of the 4 periods in Part A (dose escalation: 0.5 milligram (mg), 1.5 mg, subsequent doses determined based on review of safety, tolerability, glycaemic response and available pharmacokinetic (PK) data from the first 2 dose levels). One cohort of participants with Type 2 Diabetes Mellitus (T2DM) will receive single oral doses of LY2881835 in up to 2 of the 3 periods in Part B (dose escalation: starting dose based on review of safety, tolerability, glycaemic response and available PK data from Part A).
There is a washout period of at least 5 days between periods (doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One cohort of healthy participants will receive a single oral dose of placebo in 1 of the 4 periods in Part A. Another cohort of participants with T2DM will receive a single oral dose of placebo in 1 of the 3 periods in Part B.
There is a washout period of at least 5 days between periods (doses).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2881835</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2881835</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects:

          -  Are a healthy male or a healthy female who cannot become pregnant, or are patients
             with Type 2 Diabetes Mellitus (T2DM) who are not taking any drugs to lower blood sugar
             except metformin

          -  Have a body mass index (BMI) of at least 18.5 kilograms per meter squared (kg/mÂ²) at
             screening

          -  Have blood pressure, pulse rate and clinical laboratory tests within the normal range
             for the population or investigator site, or with abnormalities deemed clinical
             insignificant by the investigator

          -  Have veins that are suitable for easy blood collection

          -  Are reliable and willing to be available for the whole study and are willing to follow
             study procedures

          -  Must have given written informed consent

        Subjects with Type 2 Diabetes Mellitus (T2DM) only:

          -  Do not have any change to their diabetes treatment for at least 4 weeks prior to
             screening

          -  Have a glycosylated hemoglobin (HbA1c) level greater than or equal to 6% and less than
             or equal to 11% at screening

        Exclusion Criteria:

        All subjects:

          -  Are currently participating in or were in another new drug or medical research study
             in the last 30 days

          -  Have participated in this study before

          -  Have known allergies to compounds related to the study drug

          -  Currently have or used to have health problems or laboratory test results that in the
             opinion of the doctor, could interfere with understanding the results of this study

          -  Intend to use over-the-counter or prescription medications within 14 days prior to
             dosing or during the study. Hormone replacement therapy and intermittent use of
             paracetamol during the study is acceptable. For patients with Type 2 Diabetes
             Mellitus, medicines for control of high fats (For example, cholesterol), high blood
             pressure, are allowed.

          -  Have electrocardiogram (ECG) readings that are not suitable for the study

          -  Are unwilling to follow dietary restrictions/requirements for the study including 1)
             refrain from consuming foods or beverages containing grapefruit pomelo, star fruit, or
             Seville orange within 14 days of the start of the study drug dosing until collection
             of the last blood sample for drug assay and 2) consume only the meals provided during
             inpatient stays at the clinical research unit

          -  Have a history of drug or alcohol abuse

          -  Are infected with hepatitis B

          -  Are infected with human immunodeficiency disease virus (HIV)

          -  Have donated 450 milliliters (mL) or more of blood in the last 3 months or provided
             any blood donation within the last month from screening

          -  Have a regular alcohol intake greater than 21 units per week (males) and 14 units per
             week (females) or are not willing to abstain from alcohol while in the research unit

          -  Smoke more than 10 cigarettes per day or are not willing to abstain from smoking while
             at the clinic

          -  The study doctor thinks the subject should not participate for any other reasons

        Subjects with Type 2 Diabetes Mellitus (T2DM) only:

          -  Have health complications due to poorly controlled diabetes as shown by blood and
             urine laboratory test results or based on physical examination and medical assessment,
             as determined by the study doctor

          -  Were hospitalised for poor control of their diabetes (ketoacidotic episode) in the
             last 6 months

          -  Currently using or have used insulin in the last 1 year to control their diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 20, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <results_first_submitted>March 20, 2019</results_first_submitted>
  <results_first_submitted_qc>March 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2019</results_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a 2-part (Part A and Part B) crossover study with four periods.In Part A, 8 participants were dosed at each dose level in 4 study periods (1 additional participant was dosed only in 1 study period). In Part B, a single cohort of 9 participants with type 2 diabetes mellitus (T2DM) participated in 3 dosing periods.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Part A (Healthy): Sequence 1</title>
          <description>Participants received single oral doses of 0.5 milligram (mg), 1.5 mg, 4.5 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 0.5 mg LY2881835, Period 2: 1.5 mg LY2881835, Period 3: 4.5 mg LY2881835, Period 4: Placebo.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Part A (Healthy): Sequence 2</title>
          <description>Participants received single oral doses of 0.5 mg, 1.5 mg, 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 0.5 mg LY2881835, Period 2: 1.5 mg LY2881835, Period 3: Placebo, Period 4: 8.4 mg LY2881835.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1: Part A (Healthy): Sequence 3</title>
          <description>Participants received single oral doses of 0.5 mg, 4.5 mg, 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 0.5 mg LY2881835, Period 2: Placebo, Period 3: 4.5 mg LY2881835, Period 4: 8.4 mg LY2881835.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 1: Part A (Healthy): Sequence 4</title>
          <description>Participants received single oral doses of 1.5 mg, 4.5 mg, 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo, Period 2: 1.5 mg LY2881835, Period 3: 4.5 mg LY2881835, Period 4: 8.4 mg LY2881835.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 2: Part B (T2DM): Sequence 1</title>
          <description>Participants received single oral doses of 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 8.4 mg LY2881835, Period 2: 8.4 mg LY2881835, Period 3: Placebo.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 2: Part B (T2DM): Sequence 2</title>
          <description>Participants received single oral doses of 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 8.4 mg LY2881835, Period 2: Placebo, Period 3: 8.4 mg LY2881835.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 2: Part B (T2DM): Sequence 3</title>
          <description>Participants received single oral doses of 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo, Period 2: 8.4 mg LY2881835, Period 3: 8.4 mg LY2881835.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2">One participant who withdrew in period 1 was replaced by another participant in period 2.</participants>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0">Part B was planned for only 3 dosing periods.</participants>
                <participants group_id="P6" count="0">Part B was planned for only 3 dosing periods.</participants>
                <participants group_id="P7" count="0">Part B was planned for only 3 dosing periods.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants who received study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Part A (Healthy): Sequence 1</title>
          <description>Participants received single oral doses of 0.5 milligram (mg), 1.5 mg, 4.5 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 0.5 mg LY2881835, Period 2: 1.5 mg LY2881835, Period 3: 4.5 mg LY2881835, Period 4: Placebo.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: Part A (Healthy): Sequence 2</title>
          <description>Participants received single oral doses of 0.5 mg, 1.5 mg, 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 0.5 mg LY2881835, Period 2: 1.5 mg LY2881835, Period 3: Placebo, Period 4: 8.4 mg LY2881835.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1: Part A (Healthy): Sequence 3</title>
          <description>Participants received single oral doses of 0.5 mg, 4.5 mg, 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 0.5 mg LY2881835, Period 2: Placebo, Period 3: 4.5 mg LY2881835, Period 4: 8.4 mg LY2881835.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 1: Part A (Healthy): Sequence 4</title>
          <description>Participants received single oral doses of 1.5 mg, 4.5 mg, 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo, Period 2: 1.5 mg LY2881835, Period 3: 4.5 mg LY2881835, Period 4: 8.4 mg LY2881835.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 2: Part B (T2DM): Sequence 1</title>
          <description>Participants received single oral doses of 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 8.4 mg LY2881835, Period 2: 8.4 mg LY2881835, Period 3: Placebo.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 2: Part B (T2DM): Sequence 2</title>
          <description>Participants received single oral doses of 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: 8.4 mg LY2881835, Period 2: Placebo, Period 3: 8.4 mg LY2881835.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 2: Part B (T2DM): Sequence 3</title>
          <description>Participants received single oral doses of 8.4 mg LY2881835 and placebo capsules on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo, Period 2: 8.4 mg LY2881835, Period 3: 8.4 mg LY2881835.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Adverse Effects</title>
        <description>Clinically significant adverse effects are treatment emergent adverse events (TEAEs) possibly related to study drug.</description>
        <time_frame>Baseline to study completion up to 3 months</time_frame>
        <population>All enrolled participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - Placebo</title>
            <description>Single oral dose of placebo in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O2">
            <title>Part A - 0.5 mg LY2881835</title>
            <description>Single oral dose of 0.5 milligram (mg) LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O3">
            <title>Part A - 1.5 mg LY2881835</title>
            <description>Single oral dose of 1.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O4">
            <title>Part A - 4.5 mg LY2881835</title>
            <description>Single oral dose of 4.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O5">
            <title>Part A - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O6">
            <title>Part B - Placebo</title>
            <description>Single oral dose of placebo in a study period in Part B [Type 2 Diabetes Mellitus (T2DM)].</description>
          </group>
          <group group_id="O7">
            <title>Part B - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in 2 of the 3 study periods in Part B (T2DM).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Adverse Effects</title>
          <description>Clinically significant adverse effects are treatment emergent adverse events (TEAEs) possibly related to study drug.</description>
          <population>All enrolled participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under the Curve (AUC) of LY2881835</title>
        <description>Not all the participants had quantifiable plasma concentrations at 48 hours, therefore only AUC from time zero to 24 hours [AUC(0-24 hours)] is provided.</description>
        <time_frame>Part A: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24hours (h) post-dose; Part B: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose</time_frame>
        <population>All participants who received study drug and had evaluable PK data. Each participant in group Part B, Study Periods 1, 2 and 3 - 8.4 mg LY2881835 was dosed and had corresponding PK measures in 2 of the 3 study periods in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment the participants actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 0.5 mg LY2881835</title>
            <description>Single oral dose of 0.5 milligram (mg) LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O2">
            <title>Part A - 1.5 mg LY2881835</title>
            <description>Single oral dose of 1.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O3">
            <title>Part A - 4.5 mg LY2881835</title>
            <description>Single oral dose of 4.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O4">
            <title>Part A - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O5">
            <title>Part B, Study Period 1 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in Study Period 1 in Part B [Type 2 Diabetes Mellitus (T2DM)].</description>
          </group>
          <group group_id="O6">
            <title>Part B, Study Period 2 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in Study Period 2 in Part B (T2DM).</description>
          </group>
          <group group_id="O7">
            <title>Part B, Study Period 3 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in Study Period 3 in Part B (T2DM).</description>
          </group>
          <group group_id="O8">
            <title>Part B, Study Periods 1, 2, and 3 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in 2 of the 3 study periods in Part B (T2DM).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Curve (AUC) of LY2881835</title>
          <description>Not all the participants had quantifiable plasma concentrations at 48 hours, therefore only AUC from time zero to 24 hours [AUC(0-24 hours)] is provided.</description>
          <population>All participants who received study drug and had evaluable PK data. Each participant in group Part B, Study Periods 1, 2 and 3 - 8.4 mg LY2881835 was dosed and had corresponding PK measures in 2 of the 3 study periods in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment the participants actually received.</population>
          <units>nanograms*hour/milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <units_analyzed>Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" spread="39"/>
                    <measurement group_id="O2" value="125" spread="47"/>
                    <measurement group_id="O3" value="340" spread="31"/>
                    <measurement group_id="O4" value="767" spread="48"/>
                    <measurement group_id="O5" value="820" spread="20"/>
                    <measurement group_id="O6" value="683" spread="26"/>
                    <measurement group_id="O7" value="658" spread="43"/>
                    <measurement group_id="O8" value="717" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) Of LY2881835</title>
        <description>Not all the participants had quantifiable plasma concentrations at 48 hours, therefore only Cmax up to 24 hours post-dose is provided.</description>
        <time_frame>Part A: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose; Part B: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose</time_frame>
        <population>All participants who received study drug and had evaluable PK data. Each participant in group Part B, Study Periods 1, 2 and 3 - 8.4 mg LY2881835 was dosed and had corresponding PK measures in 2 of the 3 study periods in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment the participants actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 0.5 mg LY2881835</title>
            <description>Single oral dose of 0.5 milligram (mg) LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O2">
            <title>Part A - 1.5 mg LY2881835</title>
            <description>Single oral dose of 1.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O3">
            <title>Part A - 4.5 mg LY2881835</title>
            <description>Single oral dose of 4.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O4">
            <title>Part A - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O5">
            <title>Part B, Study Period 1 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in Study Period 1 in Part B [Type 2 Diabetes Mellitus (T2DM)].</description>
          </group>
          <group group_id="O6">
            <title>Part B, Study Period 2 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in Study Period 2 in Part B (T2DM).</description>
          </group>
          <group group_id="O7">
            <title>Part B, Study Period 3 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in Study Period 3 in Part B (T2DM).</description>
          </group>
          <group group_id="O8">
            <title>Part B, Study Periods 1, 2, and 3 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in 2 of the 3 study periods in Part B (T2DM).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) Of LY2881835</title>
          <description>Not all the participants had quantifiable plasma concentrations at 48 hours, therefore only Cmax up to 24 hours post-dose is provided.</description>
          <population>All participants who received study drug and had evaluable PK data. Each participant in group Part B, Study Periods 1, 2 and 3 - 8.4 mg LY2881835 was dosed and had corresponding PK measures in 2 of the 3 study periods in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment the participants actually received.</population>
          <units>nanograms/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <units_analyzed>Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.44" spread="16"/>
                    <measurement group_id="O2" value="14.7" spread="38"/>
                    <measurement group_id="O3" value="47.1" spread="25"/>
                    <measurement group_id="O4" value="89.9" spread="42"/>
                    <measurement group_id="O5" value="93.0" spread="30"/>
                    <measurement group_id="O6" value="85.1" spread="32"/>
                    <measurement group_id="O7" value="77.8" spread="21"/>
                    <measurement group_id="O8" value="85.1" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of LY2881835</title>
        <description>Not all the participants had quantifiable plasma concentrations at 48 hours, therefore only Tmax up to 24 hours post dose is provided.</description>
        <time_frame>Part A: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose; Part B: Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18 and 24 h post-dose</time_frame>
        <population>All participants who received study drug and had evaluable PK data. Each participant in group Part B, Study Periods 1, 2 and 3 - 8.4 mg LY2881835 was dosed and had corresponding PK measures in 2 of the 3 study periods in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment the participants actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - 0.5 mg LY2881835</title>
            <description>Single oral dose of 0.5 milligram (mg) LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O2">
            <title>Part A - 1.5 mg LY2881835</title>
            <description>Single oral dose of 1.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O3">
            <title>Part A - 4.5 mg LY2881835</title>
            <description>Single oral dose of 4.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O4">
            <title>Part A - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O5">
            <title>Part B, Study Period 1 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in Study Period 1 in Part B [Type 2 Diabetes Mellitus (T2DM)].</description>
          </group>
          <group group_id="O6">
            <title>Part B, Study Period 2 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in Study Period 2 in Part B (T2DM).</description>
          </group>
          <group group_id="O7">
            <title>Part B, Study Period 3 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in Study Period 3 in Part B (T2DM).</description>
          </group>
          <group group_id="O8">
            <title>Part B, Study Periods 1, 2, and 3 - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in 2 of the 3 study periods in Part B (T2DM).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of LY2881835</title>
          <description>Not all the participants had quantifiable plasma concentrations at 48 hours, therefore only Tmax up to 24 hours post dose is provided.</description>
          <population>All participants who received study drug and had evaluable PK data. Each participant in group Part B, Study Periods 1, 2 and 3 - 8.4 mg LY2881835 was dosed and had corresponding PK measures in 2 of the 3 study periods in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment the participants actually received.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.50" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.25" lower_limit="2.50" upper_limit="6.00"/>
                    <measurement group_id="O4" value="2.50" lower_limit="1.50" upper_limit="4.02"/>
                    <measurement group_id="O5" value="4.25" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O6" value="3.25" lower_limit="2.50" upper_limit="6.00"/>
                    <measurement group_id="O7" value="4.25" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O8" value="3.25" lower_limit="1.50" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Area Under the Effective Concentration Curve (AUEC)</title>
        <description>Glucose area under the serum concentration versus time curve (AUEC) was calculated using the linear trapezoidal rule from time 0 to 24 hours.</description>
        <time_frame>Part A: Predose, 1.0, 1.5, 2.5, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18 and 24 h post-dose; Part B: Predose, 1.0, 1.5, 2.5, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18 and 24 h post-dose</time_frame>
        <population>All participants who received study drug and had evaluable glucose data. Each participant in group Part B, Study Periods (SP) 1, 2 and 3-8.4 mg LY2881835 was dosed and had corresponding glucose measures in 2 of the 3 SP in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment participants actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - Placebo</title>
            <description>Single oral dose of placebo in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O2">
            <title>Part A - 0.5 mg LY2881835</title>
            <description>Single oral dose of 0.5 milligram (mg) LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O3">
            <title>Part A - 1.5 mg LY2881835</title>
            <description>Single oral dose of 1.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O4">
            <title>Part A - 4.5 mg LY2881835</title>
            <description>Single oral dose of 4.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O5">
            <title>Part A - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O6">
            <title>Part B - Placebo</title>
            <description>Single oral dose of placebo in a study period in Part B [Type 2 Diabetes Mellitus (T2DM)].</description>
          </group>
          <group group_id="O7">
            <title>Part B - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in 2 of the 3 study periods in Part B (T2DM).</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Area Under the Effective Concentration Curve (AUEC)</title>
          <description>Glucose area under the serum concentration versus time curve (AUEC) was calculated using the linear trapezoidal rule from time 0 to 24 hours.</description>
          <population>All participants who received study drug and had evaluable glucose data. Each participant in group Part B, Study Periods (SP) 1, 2 and 3-8.4 mg LY2881835 was dosed and had corresponding glucose measures in 2 of the 3 SP in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment participants actually received.</population>
          <units>milligrams*hour/deciliter (mg*hr/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2282" spread="291"/>
                    <measurement group_id="O2" value="2448" spread="183"/>
                    <measurement group_id="O3" value="2089" spread="146"/>
                    <measurement group_id="O4" value="2354" spread="72"/>
                    <measurement group_id="O5" value="2159" spread="133"/>
                    <measurement group_id="O6" value="3640" spread="711"/>
                    <measurement group_id="O7" value="3769" spread="719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon-Like Peptide (Active GLP-1) Area Under the Effective Concentration Curve (AUEC)</title>
        <description>Glucagon-like peptide (active GLP-1) area under the serum concentration versus time curve (AUEC) was calculated using the linear trapezoidal rule from time 0 to 2.5 hours.</description>
        <time_frame>Part A: Predose, 1.5 and 2.5 h post-dose; Part B: Predose, 1.5 and 2.5 h post-dose</time_frame>
        <population>All participants who received study drug and had evaluable GLP-1 data. Each participant in group Part B, Study Periods (SP) 1, 2 and 3-8.4 mg LY2881835 was dosed and had corresponding GLP-1 measures in 2 of the 3 SP in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment participants actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - Placebo</title>
            <description>Single oral dose of placebo in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O2">
            <title>Part A - 0.5 mg LY2881835</title>
            <description>Single oral dose of 0.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O3">
            <title>Part A - 1.5 mg LY2881835</title>
            <description>Single oral dose of 1.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O4">
            <title>Part A - 4.5 mg LY2881835</title>
            <description>Single oral dose of 4.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O5">
            <title>Part A - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O6">
            <title>Part B - Placebo</title>
            <description>Single oral dose of placebo in a study period in Part B [Type 2 Diabetes Mellitus (T2DM)].</description>
          </group>
          <group group_id="O7">
            <title>Part B - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in 2 of the 3 study periods in Part B (T2DM).</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon-Like Peptide (Active GLP-1) Area Under the Effective Concentration Curve (AUEC)</title>
          <description>Glucagon-like peptide (active GLP-1) area under the serum concentration versus time curve (AUEC) was calculated using the linear trapezoidal rule from time 0 to 2.5 hours.</description>
          <population>All participants who received study drug and had evaluable GLP-1 data. Each participant in group Part B, Study Periods (SP) 1, 2 and 3-8.4 mg LY2881835 was dosed and had corresponding GLP-1 measures in 2 of the 3 SP in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment participants actually received.</population>
          <units>picomoles*hour/liter (pmol*h/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.029" spread="1.097"/>
                    <measurement group_id="O2" value="3.277" spread="1.032"/>
                    <measurement group_id="O3" value="2.838" spread="0.759"/>
                    <measurement group_id="O4" value="3.113" spread="1.389"/>
                    <measurement group_id="O5" value="3.362" spread="0.938"/>
                    <measurement group_id="O6" value="4.249" spread="2.140"/>
                    <measurement group_id="O7" value="5.268" spread="2.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-Peptide Area Under the Effective Concentration Curve (AUEC)</title>
        <description>C-Peptide area under the serum concentration versus time curve (AUEC) was calculated using the linear trapezoidal rule from time 0 to 6 hours.</description>
        <time_frame>Part A: Predose, 1.0, 1.5, 2.5, 4, 5, 6 and 24 h post-dose; Part B: Predose, 1.0, 1.5, 2.5, 4, 5, 6 and 24 h post-dose</time_frame>
        <population>All participants who received study drug and had evaluable C-Peptide data. Each participant in group Part B, Study Periods (SP) 1, 2, 3-8.4 mg LY2881835 was dosed and had corresponding C-Peptide measures in 2 of the 3 SP in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment participants actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A - Placebo</title>
            <description>Single oral dose of placebo in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O2">
            <title>Part A - 0.5 mg LY2881835</title>
            <description>Single oral dose of 0.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O3">
            <title>Part A - 1.5 mg LY2881835</title>
            <description>Single oral dose of 1.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O4">
            <title>Part A - 4.5 mg LY2881835</title>
            <description>Single oral dose of 4.5 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O5">
            <title>Part A - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in a study period in Part A (Healthy).</description>
          </group>
          <group group_id="O6">
            <title>Part B - Placebo</title>
            <description>Single oral dose of placebo in a study period in Part B [Type 2 Diabetes Mellitus (T2DM)].</description>
          </group>
          <group group_id="O7">
            <title>Part B - 8.4 mg LY2881835</title>
            <description>Single oral dose of 8.4 mg LY2881835 in 2 of the 3 study periods in Part B (T2DM).</description>
          </group>
        </group_list>
        <measure>
          <title>C-Peptide Area Under the Effective Concentration Curve (AUEC)</title>
          <description>C-Peptide area under the serum concentration versus time curve (AUEC) was calculated using the linear trapezoidal rule from time 0 to 6 hours.</description>
          <population>All participants who received study drug and had evaluable C-Peptide data. Each participant in group Part B, Study Periods (SP) 1, 2, 3-8.4 mg LY2881835 was dosed and had corresponding C-Peptide measures in 2 of the 3 SP in Part B resulting in 18 samples being analyzed. Analysis used data according to the treatment participants actually received.</population>
          <units>picomoles*hour/liter (pmol*h/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5852.8" spread="1266.7"/>
                    <measurement group_id="O2" value="6313.7" spread="1870.3"/>
                    <measurement group_id="O3" value="7069.5" spread="2065.3"/>
                    <measurement group_id="O4" value="4962.2" spread="1192.2"/>
                    <measurement group_id="O5" value="7421.5" spread="3047.4"/>
                    <measurement group_id="O6" value="6145.6" spread="2192.4"/>
                    <measurement group_id="O7" value="6477.8" spread="2113.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to study completion up to 3 months</time_frame>
      <desc>All enrolled participants who received study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A - Placebo</title>
          <description>Single oral dose of placebo in a study period in Part A (Healthy).</description>
        </group>
        <group group_id="E2">
          <title>Part A - 0.5 mg LY2881835</title>
          <description>Single oral dose of 0.5 milligram (mg) LY2881835 in a study period in Part A (Healthy).</description>
        </group>
        <group group_id="E3">
          <title>Part A - 1.5 mg LY2881835</title>
          <description>Single oral dose of 1.5 mg LY2881835 in a study period in Part A (Healthy).</description>
        </group>
        <group group_id="E4">
          <title>Part A - 4.5 mg LY2881835</title>
          <description>Single oral dose of 4.5 mg LY2881835 in a study period in Part A (Healthy).</description>
        </group>
        <group group_id="E5">
          <title>Part A - 8.4 mg LY2881835</title>
          <description>Single oral dose of 8.4 mg LY2881835 in a study period in Part A (Healthy).</description>
        </group>
        <group group_id="E6">
          <title>Part B - Placebo</title>
          <description>Single oral dose of placebo in a study period in Part B [Type 2 Diabetes Mellitus (T2DM)].</description>
        </group>
        <group group_id="E7">
          <title>Part B - 8.4 mg LY2881835</title>
          <description>Single oral dose of 8.4 mg LY2881835 in 2 of the 3 study periods in Part B (T2DM).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

